ZLAB Investors, You Need to Know These Facts Today.

Mid-cap Healthcare company Zai Lab has moved -3.2% so far today on a volume of 100,034, compared to its average of 665,185. In contrast, the S&P 500 index moved -0.4%

Zai Lab trades -60.86% away from its average analyst target price of $93.39 per share. The 11 analysts following the stock have set target prices ranging from $70 to $199, and on average have given Zai Lab a rating of strong_buy.

Below are some factors that could be affecting the stocks's performance and analyst recommendation:

  • Based on its trailing earning per share of -3.46, Zai Lab has a trailing 12 month Price to Earnings (P/E) ratio of -10.6 while the S&P 500 average is 15.97

  • ZLAB has a forward P/E ratio of -14.5 based on its forward 12 month price to earnings (Eps) is $-2.52 per share

  • The company has a price to earnings growth (PEG) ratio of -0.17 -- a number near or below 1 signifying that Zai Lab is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 2.7 compared to its sector average of 4.07

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Based in Shanghai, the company has 1,951 full time employees and a market cap of $3,736,214,016.

If you would like more in-depth discussions of stocks such as Zai Lab, subscribe to our free newsletter!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.